• Tue, May 7, 2024

Jonathan Wolleben Maintained (BCRX) at Buy with Increased Target to $15 on, May 7th, 2024

Jonathan Wolleben of JMP Securities, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Increased Target from $14 to $15 on, May 7th, 2024.

Jonathan, nor any peers, have made any analyst calls on BCRX in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Like: 👍